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Background: It has been documented that variations exist in breast cancer treatment despite wide dissemination
of clinical practice guidelines. The aim of this population-based study was to evaluate the impact of regional
guidelines (Piedmont guidelines, PGL) for breast cancer diagnosis and treatment on quality-of-care indicators in the
Northwestern Italian region of Piedmont.
Methods: We included two samples of women aged 50–69 years with incident breast cancer treated in Piedmont
before and after the introduction of PGL: 600 in 2002 (pre-PGL) and 621 in 2004 (post-PGL). Patients were randomly
selected among all incident breast cancer cases identified through the hospital discharge records database. We
extracted clinical data on breast cancer cases from medical charts and ascertained vital status through linkage with
town offices. We assessed compliance with 14 quality-of-care indicators from PGL recommendations, before and
after their introduction in clinical practice.
Results: Among patients with invasive lesions, 77.1% (N = 368) and 77.5% (N = 383) in the pre-PGL and post-PGL
groups, respectively, received breast conservative surgery (BCS) as a first-line treatment. Following BCS, 87.7%
received radiotherapy in 2002, compared to 87.9% in 2004. Of all patients at medium-to-high risk of distant
metastasis, 65.5% (N = 268) and 63.6% (N = 252) received chemotherapy in 2002 and in 2004, respectively. Among
the 117 patients with invasive lesions and negative estrogen receptor status in 2002, hormonal therapy was
prescribed in 23 of them (19.6%). The incorrect prescription of hormonal therapy decreased to 10.8% (N = 10)
among the 92 estrogen receptor-negative patients in 2004 (p < 0.01).
Compliance with PGL recommendations was already high in the pre-PGL group, although some quality-of-care
indicators did not reach the standard. In the pre/post analysis, 8 out of 14 quality-of-care indicators showed an
improvement from 2002 to 2004, but only 4 out of 14 reached statistical significance. We did not find any change
in the risk of mortality in the post-PGL versus the pre-PGL group (adjusted hazard ratio 0.94, 95%CI 0.56–1.56).
Conclusions: These results highlight the need to continue to improve breast cancer care and to measure
adherence to PGL.
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Evidence-based guidelines serve as a tool to ensure that
patients receive treatment based on the best available
evidence. In 1995, Sainsbury et al. postulated that the
improvement of clinical practice in breast cancer treat-
ment could increase 5-year survival by up to 10% [1].
In the Piedmont Region (Northwestern Italy, popula-
tion 4.25 million), clinical practice guidelines (PGL) for
the treatment of breast cancer were first released in July
2002 and disseminated to all relevant clinicians and
other stakeholders [2,3] Furthermore, as from 1996, the
Piedmont Region has been covered by a breast screening
program for all resident women aged 50–69 years.
It has been well documented that there is considerable
variation in breast cancer treatment despite wide dis-
semination of clinical practice guidelines [4]. Variations
are usually related not only to patient characteristics,
such as age and educational level, but also to geographic
area of residence and hospital and physician characteris-
tics [5].
Although several studies have examined the different
surgical and medical breast cancer treatments employed
following the publication of clinical practice guidelines,
to our knowledge few reports have included a compari-
son with clinical practice prior to guideline publication,
and even fewer have examined the impact of guidelines
in clinical practice at a population level [6,7].
To evaluate the real impact of PGL on breast cancer
treatment in Piedmont, we collected data from the
medical charts of women with breast cancer aged
50–69 years to assess compliance with 14 quality-of-care
indicators, based on PGL recommendations, before and
after the introduction of PGL in clinical practice. Fur-
thermore, we explored the use of post-surgical medical
treatment, including radiotherapy, chemotherapy and
hormonal therapy in the two periods, according to FIGO
stage, lymph node involvement and hormone receptor
status. Finally, we compared the survival rates of patients
treated before and after the introduction of PGL.
Methods
Population and data sources
The Piedmont hospital discharge records (HDR) data-
base was used to identify female patients with incident
breast cancer, aged 50–69 years, residing in Piedmont
and surgically treated in 2002 and 2004 at regional
hospitals. In 2002 we identified 1,764 female patients, of
whom 866 underwent surgical treatment in the first
6 months of 2002. Among these 866 patients, 600 were
randomly selected for this study (pre-PGL group). In
2004, 1,777 female patients were identified, of whom
905 underwent surgical treatment in the first 6 months
of 2004. Among those 905 patients, 621 were randomly
selected for this study (post-PGL group) (Figure 1). Thestart of the post-PGL period was 1.5 years after the
introduction of PGL, as at this time they were likely to
have been implemented in Piedmont hospitals.
We did not include prevalent breast cancer cases,
i.e., women who had been previously hospitalized for
breast cancer and were recorded in the Piedmont
Cancer Registry and/or were in the HDR database
between 1998 and 2002.
For the purposes of this study, breast cancer was defined
by the following International Classification of Diseases 9th
Revision – Clinical Modification (ICD9-CM) codes: 174,
carcinoma of the breast; 233.0, in situ carcinoma of the
breast; 238.3, neoplasm of uncertain behavior of the breast;
or 239.3, neoplasm of unspecified nature of the breast, in
any position of the HDR database.
Fifty-eight patients from the randomly-selected pre-
PGL group and 71 patients from the randomly-selected
post-PGL group were not eligible for inclusion as they
had benign lesions, prevalent lesions, recurrences, other
cancers, no surgical treatment, or unavailable clinical
records. After exclusion, 542 patients were left in the
pre-PGL group and 550 in the post PGL-group, and
were included in the following analyses (Figure 1).
In situ carcinomas of the breast were over-sampled in
both groups. To do this, the same inclusion criteria were
applied, but were not restricted to the first 6 months of
2002 and 2004. Instead, all women with in situ carci-
noma (ICD9-CM code 233.0) who were surgically
treated at any time in 2002 and 2004 were included. The
total number of oversampled patients with in situ lesions
was 121 in 2002 and 108 in 2004. This over-sampling
was only used in the analyses concerning the indicators
for patients with carcinoma in situ (CIS) in order to
increase the power of the study.
The accuracy of the method adopted to identify inci-
dent breast cancer cases was validated using data from
the Piedmont Cancer Registry, which covers about 20%
of the regional population [8], as a gold standard. The
sensitivity of the algorithm was 76.7% for breast cancer
and the positive predictive value was 92.6%.
Follow-up of patients from both groups was performed
through linkage to different databases using two hierar-
chical linkage keys. The HDR database was used to identify
all subsequent relevant hospitalizations (2002–2005) for
other surgical treatments (on the same, or other lesions),
medical complications and chemotherapy sessions. Radio-
therapy was assessed through linkage with the radiotherapy
outpatient record database (which also includes extra-
regional radiotherapy records), and hormonal therapy was
assessed though linkage to the pharmaceutical prescription
record database (which includes all drug prescriptions
reimbursed to patients by the public health system).
All clinical records of any surgical or radiotherapy
hospitalization identified for patients in the HDR
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Figure 1 Study population of women with incident breast cancer who underwent surgery in 2002 and 2004.
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extracted from medical charts by two breast cancer
screening technicians supervised by a gynecologist
and an epidemiologist, working independently of the
practitioners caring for patients in different hospitals.
It was impossible to extract data blinded to the year
of treatment since the data were obtained directly
from the patients’ records. To control the extracted
data, a random 10% sample was rechecked by the
supervisors, blinded to the previous decisions. The
collected data were entered into a database previously
used for clinical audit (the Audit System on Quality
of Breast Cancer Treatment), developed by a multi-
disciplinary team from the European Breast Cancer
Network [9].
The ascertainment of vital status was carried out
through linkage with town offices, identifying the date
of death and allowing for the retrieval of the death
certificate to identify the specific causes of death
(2002–2010). All procedures concerning death certi-
ficates, data collection and coding were applied
uniformly to both groups.Main outcome measures
Fourteen quality-of-care indicators were chosen to evalu-
ate the impact of PGL (Table 1). We explored the use of
the sentinel lymph node (SLN) technique by surgical unit
annual case load, to measure the introduction of this pro-
cedure. Finally, we investigated post-surgical medical
treatment, including chemotherapy among patients with
invasive lesions at low/medium to high risk of distant
metastasis (according to the Goldhirsch scheme) [10], and
hormonal therapy prescribed according to estrogen recep-
tor status.
Statistical analyses
The differences in distribution between post-PGL and
pre-PGL breast cancer cases according to patient, tumor
and surgical unit characteristics and in the rates of
patients receiving post-surgical medical treatment were
assessed by two-way Chi square Test or Fisher Exact Test.
The 14 quality-of-care indicators (Table 1) were ana-
lyzed as dichotomous variables by multivariable logistic
regression models, using the period (post-PGL versus
pre-PGL) as the main effect and controlling for
Table 1 Piedmont Region clinical practice guidelines quality-of-care indicators
Level of evidence (AHRQ
grade of underlying
recommendation)
Quality-of-care indicators Function Quality-of-
care
standards
B % of malignant lesions with
cytological or histological pre-
operative diagnosis
Calculates the proportion of patients with invasive or in situ
lesions with a pre-operative cytological or histological diagnosis
(C5 or B5), out of the total number of patients with invasive or in
situ lesions who underwent surgical treatment.
≥ 70%
A % BCS in pT1, unifocal Calculates the proportion of patients diagnosed with invasive
lesions of a pathological size of ≤20 mm (pT1, microinvasive
included), not clinically multicentric or multifocal, who were
treated with BCS.
≥ 80%
B % BCS with free margins (>1 mm) Calculates the proportion of BCS (last BCS if more than one) for
invasive or in situ lesions which ensured clear margins (distance
>1 mm from the lesion), out of the total number of BCS
performed.
/
/ % single surgery after diagnosis Calculates the proportion of patients whose first surgical
treatment was not followed by further local operations that were
required due to incomplete excision (excluding failed biopsies),
out of the total number of patients who were surgically treated
for localized invasive or in situ lesions with a positive or
suspicious cytological or histological pre-operative diagnosis.
/
C % frozen section in lesions ≤10 mm Calculates the proportion of patients surgically treated for
invasive lesions (excluding microinvasive lesions) of a maximum
pathological size ≤10 mm for which there was no frozen section,
out of the total number of patients with the same diagnosis.
≥ 95%
A % of patients with invasive lesions
treated with axillary clearance or
SLN technique
Calculates the proportion of patients with invasive lesions who
were treated with axillary dissection or SLN technique, out of the
total number of patients with invasive lesions.
/
C % of patients treated with axillary
clearance with >9 lymph nodes
Calculates the proportion of patients with invasive lesions who
were treated with axillary clearance (level I-III), excluding
sampling, and from whom at least 10 lymph nodes were excised,
out of the total number of patients with invasive lesions who
were treated with axillary clearance.
≥ 95%
C % with NO dissection among CIS
patients
Calculates the proportion of patients diagnosed with CIS or not
otherwise specified in situ lesions (microinvasive cancer excluded)
on whom no axillary dissection was performed (not even level I)
out of the total number of patients with this diagnosis who were
surgically treated.
≥ 95%
C % correct SLN identification Calculates the% of SLN identified out of the total of identified
SLN in patients with invasive lesions, who were treated with SLN
technique.
≥ 90%
C % histopathological grading
available
Calculates the proportion of patients with invasive lesions
(excluding microinvasive cancer) who were surgically treated and
for whom measuring was provided, out of the total number of
patients with invasive lesions who underwent surgical treatment.
≥ 95%
C % hormonal receptor availability Calculates the proportion of patients with invasive lesions
(excluding microinvasive cancer) who were surgically treated and
for whom measuring was provided, out of the total number of
patients with invasive lesions who underwent surgical treatment.
≥ 95%
/ % immediate reconstruction after
mastectomy
Calculates the proportion of patients with invasive or in situ
lesions who had mastectomies and immediate reconstruction,
out of the total number of patients treated with mastectomy.
/
A % radiotherapy in patients treated
with BCS
Calculates the proportion of patients who were treated with BCS
for invasive or in situ lesions, and for whom radiotherapy
followed, out of the total number of patients with the same
diagnosis who were treated with BCS.
≥ 95%
A % of eligible patients that receive
hormonal therapy
Calculates the proportion of patients with invasive lesions and
positive estrogen receptors who received hormonal therapy.
/
AHRQ grade of underlying recommendation (reference http://archive.ahrq.gov/clinic/epcarch.htm), BCS: breast conservative surgery, pT1: small primary tumor,
SLN: sentinel lymph node, CIS: carcinoma in situ.
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Table 2 Distribution of breast cancer cases according to various patient, tumor and surgical unit characteristics, 2002
and 2004, Piedmont Region, Italy
N and% of patients Effect of year
2002 2004 (p value)
Sample size (N) 542 (49.6%) 550 (50.4%)
Age (years)
50–54 134 (24.7%) 124 (22.5%) 0.35
55–59 111 (20.5%) 122 (22.2%)
60–64 166 (30.6%) 151 (27.5%)
65–69 131 (24.2%) 153 (27.8%)
Missing 0 0
Educational level
Bachelor 69 (12.7%) 99 (18.0%) 0.11
Secondary 151 (27.9%) 146 (26.5%)
Professional 222 (40.9%) 197 (35.8%)
Intermediate and primary 85 (15.7%) 88 (16.0%)
None and unknown 15 (2.8%) 20 (3.6%)
Pathological T stage
In Situ 62 (11.4%) 55 (10.0%) 0.54
1mic 10 (1.8%) 15 (2.7%)
1 4 (0.7%) 5 (0.9%)
1a 17 (3.2%) 25 (4.5%)
1b 75 (13.8%) 85 (15.5%)
1c 186 (34.3%) 189 (34.4%)
2 147 (27.2%) 136 (24.7%)
3 5 (0.9%) 10 (1.8%)
4 5 (0.9%) 5 (0.9%)
4a 3 (0.6%) 0 (0%)
4b 18 (3.3%) 15 (2.7%)
4c 1 (0.2%) 0 (0%)
4d 2 (0.4%) 2 (0.4%)
X 4 (0.7%) 2 (0.4%)
Missing 3 (0.6%) 6 (1.1%)
Pathological N stage
0 205 (43.3%) 158 (31.3%) <0.01
Sentinel lymph node 80 (16.9%) 167 (33.1%)
1 21 (4.4%) 37 (7.3%)
1a 20 (4.2%) 72 (14.3%)
1b 7 (1.5%) 3 (0.6%)
1b1 40 (8.4%) 2 (0.4%)
1b2 7 (1.5%) 3 (0.6%)
1b3 56 (11.8%) 3 (0.6%)
1b4 11 (2.3%) 3 (0.6%)
2 15 (3.2%) 25 (5.0%)
3 0 23 (4.6%)
X 9 (1.9%) 6 (1.2%)
Missing 2 (0.4%) 2 (0.4%)
Sacerdote et al. BMC Health Services Research 2013, 13:28 Page 5 of 12
http://www.biomedcentral.com/1472-6963/13/28
Table 2 Distribution of breast cancer cases according to various patient, tumor and surgical unit characteristics, 2002
and 2004, Piedmont Region, Italy (Continued)
Pathological TNM stage
In situ 65 (12.0%) 56 (10.2%) 0.04
I 189 (34.8%) 233 (42.3%)
II A 127 (23.4%) 112 (20.4%)
II B 75 (13.8%) 53 (9.6%)
III or more 47 (8.8%) 65 (11.9%)
Missing 39 (7.2%) 31 (5.6%)
Grading (invasive only)
Low 58 (12.0%) 82 (16.5%) 0.09
Intermediate 69 (14.4%) 86 (17.4%)
High 103 (21.5%) 89 (18.4%)
Not performed and missing 250 238
Disease detected through regional screening program
Yes 208 (38.4) 236 (42.9%) 0.001
No, symptomatic 209 (38.6%) 171 (31.9%)
No, asymptomatic 110 (20.3%) 112 (20.4%)
Missing 15 (2.8%) 31 (5.6%)
Surgical unit annual case load
< 50 124 (22.9%) 126 (22.9%) 0.001
50–149 249 (45.9%) 250 (45.5%)
≥ 150 155 (28.6%) 147 (26.8%)
Missing 14 (2.6%) 27 (4.8%)
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ing provenience and surgical unit annual case load). The
results are presented as frequencies, adjusted odds ratios
(ORadj) and 95% confidence intervals (95%CI) estimated
from logistic models to measure the probability of achie-
ving standards in 2004 compared to 2002. We performed
Cox proportional hazards regression analyses to study
survival. Proportional hazard assumptions were tested with
the Grambsch and Therneau test before analysis. Statistical
analyses were performed using SAS 8.2 and STATA v10.
Results
Patient characteristics
Among the women included in the analyses, the distribu-
tion by type of lesion in the pre-PGL group was: 88.0%
invasive or microinvasive (N = 477) (ICD9-CM code 174),
and 12.0% in situ (N = 65) (ICD9-CM code 233.0); in the
post-PGL group it was 89.8% invasive or microinvasive
(N = 494), and 10.2% in situ (N = 56) (non-statistically
significant difference) (Table 1).
Table 2 shows the distribution of breast cancer cases by
patient, tumor and care provider characteristics for the pre-
PGL and post-PGL groups. Both groups had similar age
and educational level distribution. In contrast, there was astatistically significant difference in the distribution of
clinical stages between 2002 and 2004. The proportion of
cases diagnosed through the regional screening program
increased from 38.4% (N = 208) in 2002 to 42.9% (N = 236)
in 2004 (p = 0.001). Of all patients diagnosed with CIS, the
percent diagnosed by the regional screening program
increased from 45.9% (N = 28) in 2002, to 63.6% (N = 35)
in 2004 (data not shown). The annual case load of surgical
units was stable over the two periods (Table 2).Surgical and medical treatment
In the pre-PGL group 77.1% (N = 368) of patients with
invasive lesions received BCS as a first-line treatment, and
for 62.7% (N = 299) of patients in the pre-PGL group, BCS
was a definitive surgical treatment. In the post-PGL group
the numbers were 77.5% (N = 383) and 66.6% (N=329),
respectively (Figure 2).
As for post-surgical medical treatment, following BCS,
87.7% (N = 341) of the pre-PGL group and 87.9%
(N = 362) of the post-PGL group received radiotherapy
alone, or in combination with chemotherapy (Figure 3).
Post-surgical treatment with adjuvant chemotherapy was



































































































Mast: mastectomy, BCS: breast conservative surgery.
Figure 2 Surgical treatment in women with incident breast cancer who underwent surgery during the first 6 months of 2002
and 2004.
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46.2% (N = 254) of the post-PGL group (about 39% follow-
ing BCS and 69% following mastectomy) (data not shown).
Post-surgical medical treatment of invasive lesions is
shown in Tables 3 and 4. Of all patients with invasive
lesions at medium-to-high risk of distant metastasis,
64.6% received chemotherapy (N = 520): 65.5% in the pre-
PGL group and 63.6% in the post-PGL group. Among
113 women with invasive lesions at low risk of distant
metastasis 14.3% and 1.4% received chemotherapy in 2002
and 2004, respectively (Table 3).
Hormonal therapy was prescribed to 684 out of 901
(75.9%) patients with invasive lesions. Of women who
were prescribed hormonal therapy, 4.8% (N = 33) had
negative estrogen receptor status. The incorrect pre-
scription of hormonal therapy in patients with negative
receptor status decreased from 19.6% (N = 23) in 2002
to 10.8% (N = 10) in 2004 (p<0.01) (Table 4).
Compliance with PGL recommendations
Univariate analysis showed that compliance with PGL
recommendations was already high in the pre-PGL
group. Indeed, five of nine quality-of-care indicators did
not achieve the proposed standard (% of malignant
lesions with cytological or histological pre-operative
diagnosis, % frozen section in lesions ≤ 10 mm,% of
patients treated with axillary clearance with > 9 lymphnodes, % with no dissection among CIS patients, %
radiotherapy in patients treated with BCS).
In the pre/post analysis, studying the probability of
achieving standards in 2004 compared to 2002, although
eight of the 14 examined quality-of-care indicators changed
in the expected direction, only four indicators improved
substantially from 2002 to 2004: percent of malignant
lesions with cytological or histological diagnosis before sur-
gery (ORadj 0.64, 95% CI 0.49–0.85), percent of BCS in pT1
lesions and percent of BCS performed with free margins
(ORadj 0.41, 95% CI 0.22–0.75 and ORadj 0.65, 95% CI
0.41–1.01 respectively) and percentage of frozen section in
lesions ≤ 10 mm (ORadj 0.32, 95% CI 0.16–0.65). The other
indicators were stable in the two periods (Table 5).
The number and percent of women treated with SLN
technique by surgical unit annual case load is shown in
Table 6. The PGL recommendations said that the SLN
technique should be performed, as an alternative to axil-
lary dissection, only by surgical units with a high annual
case load. The percent of patients who were treated with
SLN technique by a surgical unit with an annual case
load of < 50 (based on the total number of women who
underwent surgery in low-case load units) was 19.1% in
2002 (N = 25) and 42.3% in 2004 (N = 55). There was a
big increase from 2002 to 2004 in the use of this tech-
nique across all strata of annual surgical case load, but
















































Some treatment:  N=350 (90%)
No treatment:  N=39 (10%)
Some treatment:  N=100 (68.5%)
No treatment:  N=46 * (31.5%)
*One patient refused CT treatment.
Some treatment:  N=374 (90.8%)
No treatment:  N=38 (9.2%)
Some treatment:  N=104 (75.9%)
No treatment:  N=33 (24.1%)
BCS: breast conservative surgery, Mast: mastectomy, RT: radiotherapy, CT: chemotherapy.
Figure 3 Post-surgical medical treatment in women with incident breast cancer who underwent surgery during the first 6 months of
2002 and 2004.
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increase, ≥ 150 = 41% increase) (Table 6).Survival analyses
Between 2002 and 2010, a total of 101 deaths were identified:
52 women in the pre-PGL and 49 in the post-PGL group
(90.4% and 90.1% crude 5–year survival, respectively).
We did not find any change in the risk of mortality in
the post-PGL versus the pre-PGL group (HR 0.94, 95%CI
0.56–1.56 adjusted for age, clinical stage and surgical unit
annual case load).Discussion
This study evaluated compliance with PGL for breast
cancer by comparing cases treated before and after their
introduction. Patient and tumor characteristics were
comparable between pre-PGL and post-PGL patients
and the same methods of ascertainment and data collec-
tion were used.Table 3 Post-surgical chemotherapy by risk of distant
metastasis according to ER and lymph node status, 2002
and 2004, Piedmont Region, Italy
Low Risk* Medium-to-high risk§ p
valueN and % N and %





* ER-positive and size ≤ 2 cm and grading=1 with negative lymph node status.
§ ALL patients with positive lymph node status or estrogen receptor-negative
or size > 2 cm or grading ≥ 2 regardless of lymph node status.In a previous report we investigated the distribution,
implementation and evaluation of PGL among clinicians
who treat breast cancer in the Piedmont Region. We
found that approximately 90% of surgeons, gynecolo-
gists, oncologists and radiologists working in the field
(70.2% of those who responded to the questionnaire),
were aware of PGL within 1 year of their release, and
generally had a positive attitude to change their practice
accordingly [3].
In this population-based study we examined clinical
practice patterns before and after the introduction of
PGL. We and observed good compliance with PGL
before their release, and a weak increase in the number
of medical decisions that complied with them after their
release.
The literature contains several examples of situations
in which clinical practice guidelines on breast cancer
treatment contributed to an improvement in quality of
care [6,7,11,12], but very few of them included a compari-
son of clinical practice prior to the release of the guidelines
[6], or examined this practice at a population level [7].Table 4 Post-surgical hormonal therapy in patients with
invasive lesions according to estrogen receptor (ER)







N and % N and %




Table 5 Achievement of Piedmont Region clinical practice guidelines quality-of-care standards in 2002 and 2004, and
effects of year, Piedmont Region, Italy
Results Effect of year (adjusted* OR and 95%CI)
2002 vs 20042002 2004
N and % Missing N and % Missing
% of malignant lesions with cytological or
histological pre-operative diagnosis
297/513 48 329/495 65 0.64 (0.49-0.85)
(57.9%) (8.6%) (66.5%) (11.6%)
% BCS in pT1, unifocal 231/268 0 253/272 0 0.41 (0.22-0.75)
(86.2%) (93.0%)
% BCS with free margins (> 1 mm) 312/368 33 348/387 33 0.65 (0.41-1.01)
(84.8%) (8.2%) (89.9%) (7.9%)
% single surgery after diagnosis 332/369 4 342/376 8 1.02 (0.24-5.91)
(90.0%) (1.1%) (91.0%) (2.1%)
% frozen section in lesions ≤ 10 mm 55/97 1 85/113 0 0.32 (0.16-0.65)
(56.7%) (1.0%) (75.2%)
% of patients with invasive lesion treated
with axillary clearance or SLN technique
433/468 0 460/478 1 0.28 (0.10-0.85)
(92.5%) (96.2%) (0.2%)
% of patients treated with axillary
clearance with > 9 lymph nodes
317/336 4 245/268 4 1.71 (0.89-3.31)
(94.3%) (1.2%) (91.4%) (1.5%)
% with NO dissection among CIS patients** 115/123 0 98/104 0 0.60 (0.14-2.50)
(93.5) (94.2%)
% correct identification of SLN 118/126 30 215/219 54 0.46 (0.18-1.05)
(93.6%) (19.2%) (98.2%) (19.8%)
% histopathological grading available 455/462 18 466/469 17 0.34 (0.08-1.42)
(98.5%) (3.7%) (99.4%) (3.5%)
% hormonal receptor availability 455/471 9 446/473 13 1.80 (0.94-3.48)
(96.6%) (1.8%) (94.3%) (2.7%)
% immediate reconstruction after mastectomy 41/154 4 30/137 2 1.16 (0.63-2.16)
(26.6%) (2.5%) (21.9%) (1.4%)
% radiotherapy in patients treated with BCS 341/389 0 362/412 0 1.01 (0.60-1.5)
(87.7%) (87.9%)
% of eligible patients that receive hormonal therapy 319/338 0 332/354 0 1.01 (0.69-1.42)
(94.3%) (93.8%)
The 2004 period is the reference category for the estimation of ORs.
*Adjusted for age, educational level, clinical stage, screening provenience and surgical unit annual case load.
**Calculated on CIS lesions over-sampled group.
OR: odds ratio, BCS: breast conservative surgery, pT1: small primary tumor, CIS: carcinoma in situ, SLN: sentinel lymph node.
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a study in France on 200 patients, with a before/after
design, using information from medical records, and
suggested significant changes in the quality of care.
These changes were probably due to the introduction of
clinical practice guidelines, but their results needed
confirmation in a larger sample of cases.
White and collaborators [7] performed a study in
Victoria, Australia in 2004 with a similar design using
mailed questionnaires. All cases of early breast cancer
registered in the Victorian Cancer Registry during two6–month periods were selected and a questionnaire was
sent to the relevant surgeon about patient characteristics
and primary treatments. The study showed an improve-
ment in quality of care after the introduction of clinical
practice guidelines. However the study included data
provided directly by surgeons from two different surveys.
Significantly more surgeons completed the questionnaire
in the first survey (73%) than in the second one (52%).
The difference in the response rate between the two
surveys could have introduced bias, causing a selection of
those most interested in the topic, i.e., the surgeons with
Table 6 Surgical treatment with sentinel lymph node
technique according to surgical unit annual case load,
2002 and 2004, Piedmont Region, Italy
Surgical unit
annual case load
Sentinel lymph node technique
2002 2004
N and % Missing N and % Missing
< 50 25/131 3 55/130 3
(19.1%) (2.2%) (42.3%) (2.2%)
50–149 67/244 7 113/250 1
(27.4%) (2.8%) (45.2%) (0.4%)
≥ 150 55/146 8 95/149 0
(37.7%) (5.2%) (63.7%)
Overall 147/521 21 263/529 21
(28.2%) (3.9%) (49.7%) (3.8%)
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by the physicians could have reflected not necessarily what
they did in their clinical practice, but what they knew they
should have done to comply with the guidelines.
In our study we collected data directly from clinical
records. We found a statistically significant positive trend
in two of four quality-of-care indicators concerning diagno-
sis. In particular we found an improvement in the two indi-
cators that were farthest from the standard in the pre-PGL
group (% lesions with cytological/histological diagnosis
before surgery and% frozen sections in ≤ 10 mm lesions),
but not in the two indicators that already have a good
compliance with PGL (percent of histopathological grading
available and percent of hormone receptor available).
We measured two important quality-of-care indicators
concerning the surgical treatment of breast cancer: per-
cent of BCS in pT1 lesions and percent of BCS performed
with free margins, and the results were positive. We
noticed a trend of improvement in the post-PGL group:
93% of patients with pT1 were treated surgically with
BCS in the present study. We found a similar positive
trend concerning the practice of BCS over a 5–year
period (2000–2004) in a previous population-based
study on women with breast cancer (all ages) carried
out in the Piedmont Region using administrative data
[14]. Nevertheless, the percentage of single surgery
after diagnosis, which was already good before PGL
were released, and the percent of reconstruction after
mastectomy, which was extremely low, did not show a
positive trend over time.
The indicators regarding axillary surgery showed an
increased proportion of patients that were treated with
axillary clearance with a correct indication. The percent
of patients with a clearance of > 9 lymph nodes and the
percent of dissections not performed among CIS
patients did not reach the standard and did not improve
after the release of PGL. Conversely, a higher number ofcenters performed the SLN technique, with an identifi-
cation rate that reached the standard.
Finally, looking at the proportion of women who
underwent SLN technique by the annual case load of the
surgical unit, we found that the use of this technique
increased by almost 45% from 2002 to 2004, across all
strata of surgical unit annual caseload but in particular
in centers treating less than 50 breast cancer a year. This
finding is clearly in contrast with the PGL recommenda-
tions that suggest the use of SLN technique only in
specialized centers (surgical unit annual case load > 50).
The increase of use of SLN technique in low caseload
centers need to be discouraged.
Between 2002 and 2004 the proportion of women who
received radiotherapy after breast cancer surgery (87.7%
in 2002 and 87.9% in 2004) was stable, though still far
from the standard of 95%. In a previous population-
based study in Piedmont, the presence of a radiotherapy
unit within the same hospital where the surgical pro-
cedure was performed was associated with a higher
probability of receiving radiotherapy after discharge. The
presence of a radiotherapy unit in the hospital also
correlated with the case load and specialization of the
surgical unit [14].
In the analyses of post-surgical medical treatment we
found a decrease in the percent of patients with invasive
lesions at medium-to-high risk of distant metastasis who
received chemotherapy after the introduction of PGL.
Furthermore, we observed a decrease in the percent of
patients with invasive lesions and low risk of distant
metastasis who received inappropriate chemotherapy.
The percent of patients who received hormonal therapy
was stable in the group with positive estrogen receptor
status, and the incorrect prescription of hormonal treat-
ment in estrogen receptor-negative women dramatically
decreased in the post-PGL group.
Apart from the introduction of PGL, the positive trend
in some of quality-of-care indicators can be partly attribu-
ted to the increased proportion of breast cancer cases
diagnosed through the regional screening program. In fact,
the patients who were diagnosed in the context of the
screening program were usually referred to a surgical unit
with a high annual case load.
Underestimation of chemotherapy, radiotherapy and/or
hormonal therapy was possible given that these treatments
are administrated at a different hospital admission than that
for the surgical treatment, or even on an ambulatory basis.
The information we collected about post-surgical medical
treatment was the result of record-linkages between breast
cancer patients and the HDR database, radiotherapy out-
patient record database and pharmaceutical prescription
record database. Such linkages can generate omissions
that are likely to be random, so the resulting bias would
be conservative.
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between pre-PGL and post-PGL groups. In fact, the
majority of PGL recommendations were oriented to avoid
invasive surgery, over-treatment, recurrence, or patient
anxiety (i.e., avoid mastectomy in pT1 unifocal, avoid
more than one surgery after diagnosis, avoid dissection in
CIS patients). Very few recommendations were formu-
lated to improve survival (i.e., to measure hormonal recep-
tor availability, to perform radiotherapy in patients treated
with BCS, to perform axillary clearance or SLN technique
in patients with invasive lesions). Moreover the indicators
more related to survival, with the exception of axillary
clearance, showed only a negligible improvement after the
introduction of PGL. Finally it is possible that, since breast
cancer is generally characterized by long survival, a small
improvement in survival will manifest itself only with
longer follow-up.
The population-based approach of the study ensures
that selection bias was minimal and that the results can
be considered representative of the entire Piedmont
Region.Conclusions
The results suggest that the majority of quality-of-care
indicators changed in the expected direction after the
introduction of PGL, even if only 4 out of 14 reached sta-
tistical significance. Statistical significance was registered
in particular in the indicators that were far from achieving
the standard. Our results highlight the need to continue
to improve breast cancer care and to measure the correct
adherence to PGL.
In a previous study we evaluated the distribution, im-
plementation and acceptance of PGL among medical
doctors, and in the present paper we present the
results based on quality-of-care indicators before and
after the introduction of PGL. The ultimate evaluation
must involve long-term outcome studies on recurrence
and mortality to assess the real impact of PGL on
patient care, and economic evaluations to assess treat-
ment choices.Abbreviations
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